Privi Speciality Chemicals (PRIVISCL) Q2 24/25 earnings summary

Executive summary

• Achieved record quarterly revenue, surpassing Rs 500 crore for the first time, with 16% YoY growth in Q2 FY25 and 14% YoY growth for H1 FY25.

• Net profit for Q2 FY25 stood at Rs 44.8 crore, up 48% YoY; H1 FY25 PAT at Rs 76.3 crore, up 119% YoY.

• EBITDA margins exceeded 20% for the quarter, driven by improved product mix and operational efficiencies.

• Key products DHMOL, AmberFleur, and Galaxmusk operated at optimal capacity; new products Indomerane and Florovane contributed meaningfully.

• The company operates in a single segment: Aroma Chemicals.

Financial highlights

• Q2 FY25 revenue at Rs 532.8 crore, up 16% YoY; H1 FY25 revenue at Rs 1,003.9 crore, up 14% YoY.

• Q2 FY25 EBITDA at Rs 114.7 crore, up 19% YoY; H1 FY25 EBITDA at Rs 211.7 crore, up 35% YoY.

• Q2 FY25 PAT at Rs 44.8 crore, up 48% YoY; H1 FY25 PAT at Rs 76.3 crore, up 119% YoY.

• Total volumes in Q2 FY25 reached 11,504 MT, up from 8,643 MT YoY.

• Earnings per share (EPS) for Q2 FY25 was Rs 11.93, compared to Rs 6.81 in Q2 FY24.

Outlook and guidance

• Growth strategy centers on product mix improvement, operational efficiency, and new product launches.

• Production ramp-up planned for new facilities, with fresh capex for capacity enhancement and product launches.

• Continued focus on expanding global footprint and strengthening the balance sheet.

• The Board and audit committee approved the results on October 24, 2024, and the statutory auditors issued an unmodified review conclusion.